Goldman Sachs on Spyre (SYRE): 'Initial SPY001 efficacy data bolsters confidence into remaining data readouts later this year'
Tweet Send to a Friend
Goldman Sachs analyst Paul CHoi reiterated an Early-Stage Biotech rating on Spyre (NASDAQ: SYRE).The analyst comments "Initial induction data both ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
